A New England Journal of Medicine report last year detailing sharp increases in the rate of blood clots helped take market share away from Thoratec (NSDQ:THOR) and its HeartMate II implantable heart pump, company officials said yesterday.
Q1
Is Siemens Healthcare headed for a spinout?
CareFusion ChloraPrep sales make a resurgence following kickbacks scandal
California-based CareFusion (NYSE:CFN) posted a strong 3rd quarter and narrowed its full-year sales outlook, touting strong sales growth, even for its controversial ChloraPrep surgical wipes.
Volcano adds 20 to U.S. sales force
Globus Medical posts a strong 1st quarter following robotic surgery entry
Globus Medical (NYSE:GMED) got some Wall Street love after reporting a strong 1st quarter, during which the company notched the acquisition of Excelsius Surgical.
Haemonetics closes Scotland plant, launches $100M buyback after dim quarter
Massachusetts-based Haemonetics (NYSE:HAE) is making some big moves after posting a tough 4th quarter and projecting a dim outlook for the fiscal year ahead.
Revenue surge helps Accuray narrow Q3 losses, update full-year outlook
HeartWare jumps after Q1 results beat estimates
HeartWare International (NSDQ:HTWR) shares gained more than 11% yesterday after the medical device company reported surging revenues and 1st-quarter losses that bettered analysts’ forecasts.
Masimo reverses whistleblowers’ $5.4M reward
Hologic slashes Q2 losses, shares gain nearly 8%
BD posts single-digit Q2 sales, earnings gains
Becton Dickinson & Co. (NYSE:BDX) beat Wall Street’s earnings forecast with its fiscal 2nd quarter results, but investors nonetheless sent BDX shares down slightly today.